Efficacy and safety of 131I-chTNT combined with radiofrequency ablation in treatment of advanced hepatocellular carcinoma

张登科,涂建飞,纪建松,应希慧,吴发宗,赵中伟
2015-01-01
Abstract:Objective To evaluate the efficacy and safety of 131I- chTNT combined with radiofrequency ablation in treatment of advanced hepatocel ular carcinoma. Methods Thirty four patients with hepatocel ular carcinoma were treated with radiofrequency ablation (RFA group, n=22) or radiofrequency ablation combined with 131I- chTNT(combination group, n=12 cases) and fol owed up 5~48 months, the clinical data were retrospectively analyzed. The survival and safety indicators (including liver damage, bone marrow toxicity and thyroid lesions)were analyzed and compared between two groups, Results In combination group the red blood cel s, platelets were not declined, leucocytes was significantly elevated which has statistical significance and ALT and AST increased significantly, TBIL was not changed at d7 after operation, compared with those preoperatively. There were no significant changes in thyroid function, T3, T4, TSH, FT3 and FT4 1 month after treatment compared with those preoperatively. The contrast enhanced CT or MRI results showed there were 2 cases of CR, 8 cases of PR, 1 case of SD and1 case of PD at 1 month after treatment. There was an increasing tendency of median overal survival incombination group than that in RFA group (P=0.052). Conclusion For advanced hepatocel ular carcinoma, RFA combined with vivatuxin treatment is safe and ef-fective, but it stil need large sample study to confirm.
What problem does this paper attempt to address?